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are amongst the most promising therapeutic targets for can-
cer treatment. Together with genetic testing, they may have 
a potential to serve as base for patient-adapted therapies.
Keywords HDACS · Platinum resistance · Ovarian 
cancer · Platinum · Chemotherapy · Molecular targeting
Overview of ovarian cancer
Ovarian cancer is the leading cause of death arising from 
gynaecological malignancies and the fourth most common 
form of cancer in women in developed countries, after breast, 
lung, and colorectal cancer (Permuth-Wey and Sellers 2009; 
Gayther and Pharoah 2010). Around 204,000 new cases of 
ovarian cancer are diagnosed worldwide yearly with the high-
est incidence being in the USA and Northern Europe (Rauh-
Hain et al. 2011). The disease is prevalent in older, post-
menopausal women and over 80 % of cases are diagnosed 
in women over 50 years of age (Herzog and Pothuri 2006). 
The main risk factors associated with ovarian cancer are fam-
ily history, infertility, and increasing age (Tortolero-Luna 
and Mitchell 1995; Cetin et al. 2008). The estimated risk of 
developing ovarian cancer in monozygotic twin of an affected 
patient is twice the non-twin sibling risk, implies that familial 
risk of ovarian cancer may be more related to genetic factors 
than to shared environmental effects (Gayther et al. 2007). 
Further, positive correlations were observed with dietary con-
sumption of fats and proteins (Bosetti et al. 2001).
Initial symptoms of ovarian cancer prior to diagnosis are 
non-specific and include vaginal bleeding, gastrointestinal 
discomfort, and urinary tract symptoms (Friedlander 1998). 
Further, over 95 % of epithelial ovarian cancer patients expe-
rience abdominal complaints for many months prior to their 
diagnosis (Goff et al. 2007; Lowe et al. 2009). The initial 
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diagnostic workup includes a pelvic examination, ultrasound 
examination, computed tomography scans, and a blood test 
for cancer antigen 125 (CA 125), yet none of these tech-
niques can be reliably used for early detection. CA-125 is 
a tumour marker produced by ovarian cancer cells that is 
detectable in the serum of >80 % of women with ovarian car-
cinomas (Klug et al. 1984). However, it is raised in a number 
of benign ovarian disorders as well as pregnancy, rendering 
it mostly useful for monitoring treatment response or disease 
recurrence (Tuxen et al. 1995; Marsden et al. 2000; Meyer 
and Rustin 2000). Ovarian cancer has four surgical stages 
according to the International Federation of Gynecology and 
Obstetrics (FIGO) staging system (Table 1), which outlines 
patient prognosis and treatment (Bast et al. 2009).
Ovarian cancer is broadly classified into three cellular 
and histological subtypes. The cellular classification com-
prises epithelial tumours, germ cell (ova) tumours and the 
sex cord (stromal) tumours (Kurian et al. 2005). Histologi-
cally, each ovary is covered with germinal epithelium cells 
beneath which are two regions; an outer cortex and inner 
medulla responsible for oogenesis and neurovascular sup-
port, respectively (Naora and Montell 2005). Every histo-
logical subtype of ovarian cancer has different molecular 
genetic changes underlying its progression. Epithelial ovar-
ian cancer is the most common type of malignant ovarian 
tumour, occurring in 90 % of cases. Epithelial ovarian can-
cer is morphologically divided into four distinct subtypes; 
serous is the most malignant tumour of the epithelial ovar-
ian cancer followed by endometrioid, clear cell and muci-
nous (Bowtell 2010). This review presents an overview of 
epithelial ovarian cancer, drug resistance and relapse and a 
particular focus on the role of histone deacetylase inhibi-
tors as novel drugs in the field.
Biology of epithelial ovarian cancer
Most ovarian cancers arise from the surface epithelium 
(Piek et al. 2004) yet the biological mechanism behind 
this transformation is not precisely understood. The theory 
of incessant ovulation attributes repeated disruption of the 
ovarian epithelium that leads to malignant transformation of 
the epithelial cells (Fathalla 1971; Booth et al. 1989). Fac-
tors that suppress incessant ovulation include pregnancy and 
use of contraceptive that are associated with reduced risk of 
developing ovarian cancer. Hormones including gonadotro-
pins and sex steroids are thought to influence tumorigenesis. 
Excessive gonadotropin secretion during menopause may 
increase the risk of malignant alterations in the ovaries by 
stimulating the growth of ovarian epithelial cells (Risch 
1998). It is debatable whether high androgen levels may 
increase risk of ovarian cancer. While it has been shown that 
90 % of ovarian cancer tissue were positive for the androgen 
receptor (Wang and Chang 2004) a case–controlled study 
showed no association between serum levels of androgens 
and ovarian cancer risk (Rinaldi et al. 2007).
Ovarian cancer development involves the accumulation 
of several genetic alterations that, respectively, activate or 
silence oncogenes and tumour suppressor genes (Gayther 
et al. 1997; Schuijer and Berns 2003). Inherited ovarian can-
cer comprises 5–15 % of ovarian cancer (Boyd 1998). It is 
associated with improved overall survival and better clinical 
outcome than sporadic cancer. This may be due to an ear-
lier diagnosis and subsequent earlier treatment. The BRCA1 
and BRCA2 tumour suppressor genes are the most impor-
tant predisposition genes for ovarian cancer and account for 
about 90 % of ovarian cancers in the hereditary breast and 
ovarian cancer syndrome (Gayther et al. 1997; Stratton et al. 
1997). BRCA1 and BRCA2 are key proteins that mediate 
DNA double-strand break repair (D’Andrea and Grompe 
2003). Germ line mutations in the DNA mismatch repair 
(MMR) genes (hMLH1, hMSH2, hMSH6, PMS1, PMS2) 
which are commonly associated with non-polyposis colo-
rectal cancer (HNPCC) are also associated with ovarian 
cancer. Ovarian cancer risk in HNPCC families is more than 
12 % (Prat et al. 2005). The genes associated with familial 
ovarian cancer are also involved in disease pathogenesis of 
the more prevalent sporadic ovarian cancer.
A mutation of the p53 gene is the most common genetic 
alteration in epithelial ovarian cancers. This tumour sup-
pressor gene encodes a transcription factor that has a role 
in regulating cell cycle progression, DNA repair, and cell 
Table 1  Ovarian cancer FIGO 
classification
According to the International Federation of Gynecology and Obstetrics (FIGO) staging system, ovarian 
cancer is categorised into four surgical stages (described above). These stages outline treatment options, 
and a higher stage is associated with a worse prognosis. Adapted from (Benedet et al. 2000)
Stage Description
I Ovarian cancer limited to one or both ovaries
II Cancer spread outside the ovary or ovaries, but it is inside the pelvis
III Cancer has grown outside the pelvis into the abdominal cavity or involvement of upper abdominal, 
inguinal or retroperitoneal lymph nodes
IV Cancer has spread into other body organs such as the liver or outside the peritoneal cavity
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death. The majority of early and advanced stage serous car-
cinomas have mutant p53 (Havrilesky et al. 2003; Leitao 
et al. 2004; Palmer et al. 2008). PTEN tumour suppressor 
(phosphatase and tensin homolog) is one of the mutated 
tumour suppressor genes in ovarian cancer and has a role 
in cell apoptosis, proliferation and migration (Kolasa et al. 
2006; Goff et al. 2007). The RAS family consists of three 
functional genes, Hras, K-ras, and N-ras that are involved 
in signal transduction. The K-ras mutation is a common 
feature in ovarian mucinous carcinomas (Auner et al. 
2009). The combination of activating mutations in the 
oncogenic K-ras gene and PTEN deletion plays a role in 
the development of endometrioid epithelial ovarian can-
cer (Dinulescu et al. 2005). The c-MYC proto-oncogene, 
which participates in the regulation of cellular prolifera-
tion, apoptosis and cell differentiation, has also been shown 
to be overexpressed in endometrioid and clear cell carci-
nomas (Plisiecka-Halasa et al. 2003). Genes related to the 
WNT/b-catenin and cadherin signalling pathways were 
overexpressed in high-grade serous tumours, including 
N-cadherin and P-cadherin (Tothill et al. 2008). Such data 
show that each subtype of ovarian cancer has distinct gene 
mutations. Gene expression analyses can distinguish histo-
logical subtypes based on their global gene expression pro-
files (Cho and Shih Ie 2009; Gomez-Raposo et al. 2010).
Treatment of ovarian cancer
Treatment of ovarian cancer broadly encompasses surgery, 
radiotherapy and chemotherapy. Treatment depends upon 
various parameters such as stage, the histopathologic type, 
patient’s age, patient’s desire to have children and overall 
health status (Cannistra 2004; Marcus et al. 2014). Surgery 
prior to chemotherapy depends on the size of the tumour 
and the patient condition. Platinum-based chemotherapy 
has been used to reduce the size of the tumour before sur-
gery. While neoadjuvant chemotherapy makes surgical 
operation easier, surgical reduction of tumour bulk prior 
to chemotherapy might reduce the chance of developing 
chemo-resistance (Morrison et al. 2007). Radiotherapy can 
be used to treat residual cancer after cytoreductive surgery 
and chemotherapy (Bese et al. 2009). The size and the site 
of residual disease and tumour grade determine the suc-
cessful outcome (Dembo 1983; Einhorn et al. 2003). Radi-
otherapy could enhance survival rate when combined with 
surgery and chemotherapy (Einhorn et al. 1999).
Neoadjuvant or adjuvant chemotherapy is administered 
to most ovarian cancer patients. Chemotherapy drugs are 
categorised into several groups based on their chemical 
structure and mechanism of action (Table 2). Platinum-
based agents are the first-line choice drugs. The standard 
treatment for ovarian cancer patients is combination ther-
apy using carboplatin and paclitaxel due to its effectiveness 
and favourable toxicity profile (Ozols et al. 2003). Chem-
otherapy can be administered via the oral, intravenous or 
intraperitoneal (IP) with the latter showing an improved 
progression-free survival (Markman 2001; Armstrong and 
Brady 2006). The side effects of IP therapy can be severe 
such as the toxicity, catheter-related problems, abdominal 
pain, bloating, fatigue, infection and gastrointestinal distur-
bance (Walker et al. 2006; Fung-Kee-Fung et al. 2007).
Platinum-based therapy is very effective in the treatment 
of ovarian cancer. However, patients frequently develop 
platinum resistance. Resistance can be either acquired, 
when the patients respond to the chemotherapy but then 
develop resistance afterwards or intrinsic, when the patients 
are unaffected by platinum treatment at first exposure 
(refractory). Drug resistance is a multi-factorial phenom-
enon involving various mechanisms. These can be due to 
decreased platinum uptake or increased platinum-DNA 
adduct repair and damage tolerance. Further, cellular glu-
tathione or metallothionein cause increased efflux of cispl-
atin. Alternatively, there could be alterations in the signal-
ling pathways affecting apoptosis (Kartalou and Essigmann 
2001; Wernyj and Morin 2004; Ohmichi et al. 2005).
At present there are a number of drugs that are emerg-
ing as potential therapeutics in ovarian cancer. Sorafenib 
is a receptor tyrosine kinase inhibitor. It inhibits protein 
kinases such as vascular endothelial growth factor receptor 
Table 2  Cytotoxic chemotherapy groups active in ovarian cancer and their mechanism of action (Dunton 1997; Piccart et al. 2001)
Group Action and example
Anti-metabolite drugs These interfere with DNA and RNA synthesis e.g., 5-fluorouracil
Anti-tumour antibiotics including  
topoisomerase II
These inhibit DNA and RNA synthesis leading to cell death such as doxorubicin
Plant-based compounds These are natural products of plant alkaloids that can inhibit mitosis or enzymes, thereby 
preventing protein synthesis necessary for cell like etoposide and taxanes
Alkylating agents These interfere with DNA thus prevent the cancer cells growth
Platinum-based agents are the most effective chemotherapy for ovarian cancer on whole, showing high response 
rates and long survival for advanced ovarian cancer patients such as cisplatin and 
carboplatin
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(VEGFR) and platelet-derived growth factor receptor 
(PDGFR) together with rat sarcoma proto-oncogene 
(RAS), rat fibrosarcoma protein kinase (RAF) and mito-
gen-activated protein kinase (MAPK) (Matei et al. 2011; 
Zhang et al. 2013). The expression of histone deacety-
lases (HDACs) is increased in cells undergoing epithelial-
mesenchymal transformation; however, the expression of 
HDACs was not increased in the presences of sorafenib. 
This suggests that sorafenib may block the expression of 
HDACs (Zhang et al. 2013). Some ovarian cancer patients 
on sorafenib experienced stable disease for up to 1 year in 
a phase II trial (Strumberg et al. 2005). In a phase III trial, 
patients with ERK and b-RAF positive tumours had neo-
adjuvant sorafenib at a dose of 800 mg daily. 24 % had a 
6 month progression-free survival (Matei et al. 2011). So 
far sorafenib trials have targeted patients with advance 
ovarian cancer and trials were not well-standardised; thus, 
its role in ovarian cancer has yet to be defined (Smolle et al. 
2014).
Angiogenesis is a critical step in ovarian cancer metas-
tasis; thus, anti-angiogenic drugs that target VEGF and 
PDGF have a role to play in ovarian cancer treatment (Con-
teduca et al. 2014). Bevacizumab, an anti-VEGF mono-
clonal antibody, has been tried as a single agent and in 
combination with platinum-based chemotherapy in recur-
rent or metastatic epithelial ovarian cancer (Burger et al. 
2007; Kudoh et al. 2011; Sorbe et al. 2012). The treatment 
regimens are generally well tolerated and emerging results 
suggest improved patient efficacy (McGonigle et al. 2011; 
Gavalas et al. 2013). A phase III trial showed that bevaci-
zumab improved chemotherapy efficacy and progression-
free survival in initial disease management (Burger et al. 
2011; Perren et al. 2011). Similar outcomes were obtained 
in platinum-sensitive ovarian cancer (Aghajanian et al. 
2012). Aflibercept is a fusion protein of VEGFR1 and 
VEGFR2 attached to the Fc portion of human IgG. The 
safety profile of the drug in combination with docetaxel 
is established. Preliminary results are promising and war-
rant further investigation (Coleman et al. 2011). A number 
of other anti-angiogenic drugs have undergone pre-clinical 
studies (Wedge et al. 2005; Bauerschlag et al. 2010; Kar-
lan et al. 2012). Despite their efficacy, patients can develop 
drug resistance that may be due to cancer cell utilisation of 
alternative angiogenic pathways and recruitment of vascu-
lar progenitor cells (Conteduca et al. 2014).
One mechanism that underlies ovarian tumour progres-
sion, metastasis and chemoresistance is transcriptional 
regulation. TATA-box binding protein-associated factors 
(TAFs) regulate dedifferentiated states in ovarian cancer 
(Ribeiro et al. 2014). Understanding the nuclear mecha-
nisms associated with treatment failure in ovarian can-
cer would uncover novel pharmacologic targets to treat 
patients.
Histone deacetylase (HDACS)
The biological function of histone deacetylases (HDACs)
Transcription in eukaryotic cells is influenced by the man-
ner in which DNA is packaged. DNA is packaged into 
chromatin, a highly organised protein DNA complex. The 
basic units of the chromatin are nucleosomes. It is com-
prised of four histones; two H2A, H2B dimmers and H3, 
H4 tetramer. The presence of acetylated lysine residues in 
histone tails is associated with a more relaxed chromatin 
state and gene-transcription activation, while the deacetyla-
tion of lysine residues is associated with a more condensed 
chromatin state and transcriptional gene silencing (Fig. 1) 
(Strahl and Allis 2000). Thus, the balance between histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) 
activities play a crucial role in chromatin remodelling and 
Fig. 1  Histone acetylation/deacetylation regulates transcription. The 
balance between the acetylated and deacetylated states of histones is 
mediated by two different sets of enzymes: histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). Acetylation of the histone 
tails is associated with an open chromatin structure and active tran-
scription. Conversely, removing the acetyl groups on the histone tails 
by HDAC enzyme activity is associated with condensed chromatin 
structure and transcriptional repression. Adapted from Marks et al. 
(2001)
J Cancer Res Clin Oncol 
1 3
in the regulation of gene transcription. HDACs family con-
tained 18 known enzymes.
These HDAC enzymes divided into four classes based 
on sequence similarity to the yeast (Fig. 2). The class I, II, 
and IV HDACs are zinc-dependent and class III HDACs 
(SIRT1–SIRT7) are NAD+ dependent in their enzymatic 
activity class I HDACs include HDAC1, 2, 3, and 8. They 
are 400 residues in length and are considered as nuclear 
proteins; however, HDAC3 has the ability to shuttle 
between the nucleus and the cytoplasm. Class II HDACs 
include HDAC4, 5, 6, 7, 9, and 10. These enzymes have 
the ability to shuttle between the nucleus and cytoplasm. 
In addition, class II HDACs enzymes are grouped into 
class IIa (HDAC4, 5, 7, and 9) and IIb (HDAC6 and 10) 
because class IIa enzymes have N-terminal extension of 
600 residues that are thought to have distinctive function, 
but class IIb enzymes have two catalytic domains. Class 
IV, share the common properties between class I and class 
II HDACs and includes HDAC11 as reviewed in (Verdin 
et al. 2003). Class I enzymes are ubiquitously expressed 
in humans, whereas class II enzymes show tissue specific 
expression. Three of the class IIa HDACs, HDAC4, 5 and 
9, show highest expression in heart, skeletal muscle and 
brain. The highest expression of HDAC7 is in heart and 
lung tissues. HDAC6 is predominantly expressed in testis, 
while HDAC10 is expressed in liver, spleen and kidney 
(Verdin et al. 2003). The HDACs are not redundant in their 
biological activity. Knockout mouse experiments dem-
onstrated a different function for each HDAC. The class 
I genes HDAC1 or HDAC2 knockout in mice resulted in 
embryonic or perinatal lethality, respectively. However, 
class II HDAC knockout mice were viable and fertile, 
but all display developmental abnormalities. HDAC7 null 
mouse embryos have defects in blood vessel development 
and integrity. HDAC9 null mice display defects in car-
diac muscle development, reviewed in (Lane and Chabner 
2009).
Both class I and class II HDACs act on histone substrates 
and on non-histone proteins which play important roles in 
the regulation of various cellular processes. HDAC1 has 
been reported to affect the deacetylation of the transcrip-
tion factor p53, while HDAC6 deacetylate α-tubulin and 
heat-shock protein 90 (HSP90) (Bolden et al. 2006). HDAC 
enzymes exist in multi-protein complexes and recruited to 
certain promoters by interaction with specific transcription 
factors although these enzymes are unable to bind directly 
to DNA. For example, HDAC1 and HDAC2 are thought 
to be found together in multi-protein complexes, and a 
number of transcription factors target these two enzymes 
to specific promoters to suppress transcription (MacDon-
ald and Roskams 2008). Amongst all HDAC enzymes, 
only HDAC3 has the ability to interact with class I and II 
HDACs. HDAC3 interacts with HDAC4, SMRT (silenc-
ing mediator for retinoid and thyroid receptors) and N-CoR 
(nuclear receptor co-repressor) complexes to repress tran-
scription. The suppression of HDAC4 binding to SMRT 
and N-CoR and to HDAC3 lead to a loss of enzymatic 
activity related to HDAC4. It has been reported that class 
II HDACs require an enzymatically active SMRT/N-CoR-
HDAC3 complex to regulate transcription (Grozinger et al. 
1999; Fischle et al. 2002) with the exception of HDAC6 
which contains an internal dimer including two functional 
catalytic domains and thus does not require another HDAC 
enzyme for its activity (Grozinger et al. 1999). HDAC6 has 
been shown to specifically deacetylate α-tubulin at lysine 
40. Therefore, this lysine has been used as a marker of 
microtubule stability (Piperno et al. 1987). Sirt1, a class III 
HDAC, has been reported to deacetylate the p53 gene and 
to inhibit the transcriptional activity and apoptosis medi-
ated by this gene (Cheng et al. 2003). Class II HDACs 
can deacetylate the four core histones and act like tran-
scriptional corepressors. These enzymes either act through 
transcriptional corepressors or bind directly to sequence-
specific transcription factors, such as myocyte enhancer 
factor-2 (MEF2). The MEF2 family of transcription fac-
tors is one of the important targets of class IIa HDACs. 
MEF2, major transcriptional activators for the expression 
of muscle-specific genes, also regulate other cellular pro-
grams, including neuronal survival, T cell apoptosis, and 
growth factor responsiveness. When class IIa HDACs bind 
to MEF2, it change MEF2 from being transcriptional acti-
vators into repressors. The MEF2-binding site is conserved 
amongst all four class IIa HDACs enzymes (Gregoire and 
Yang 2005).
Fig. 2  Schematic representation of class I; HDAC1, 2, 3 and 8, 
class IIa; HDAC4, 5, 7 and 9, class IIb; HDAC6 and 10 and class 
IV; HDAC11. HDAC enzymes with the structural and the functional 
domains included the capacity of the structurally diverse HDAC 
inhibitors to inhibit the activity of each HDAC classes or specific iso-
form HDACs are shown. Adapted from Bolden et al. (2006)
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The homodimeric and heterodimeric interactions of 
HDAC might indicate that these interactions are impor-
tant for the regulation of HDAC activity. Histones not only 
undergo acetylation and deacetylation but undergo different 
post-translational modifications such as; phosphorylation, 
methylation, ubiquitination and sumoylation which are 
thought to influence the chromatin structure, DNA acces-
sibility and gene expression regulation (Struhl 1998).
The role of HDACs in cancer
The role of individual histone deacetylases (HDACs) in 
the regulation of cancer cell proliferation was investigated 
using siRNA-mediated knockdown (HDAC1, HDAC2, 
HDAC3, HDAC4 and HDAC7) in HeLa cells. Proliferation 
analysis showed that knockdown of HDAC1 and HDAC3 
resulted in slower cell growth compared with HDAC4 and 
HDAC7 and that only HDAC1 and HDAC3 are important 
in cellular proliferation (Glaser et al. 2003). Another study 
showed that siRNA knockdown of HDAC2 can arrest the 
cell cycle either at the G(1) phase or during G(2)/M transi-
tion, resulting in the loss of mitotic cells and cell growth 
inhibition. In contrast, HDAC2 knockdown showed no 
effect on cell proliferation (Senese et al. 2007). Further-
more, HDACs 1 and 2 share a high degree of homology and 
coexist within the same protein complexes. In spite of their 
close association, each possesses unique functions. High 
expression of HDAC2 has been seen in colorectal cancer 
at polyp stage (more than HDAC1 expression), suggest-
ing that HDAC2 might be involved in the early events of 
cancer development (Huang et al. 2005). The up-regulation 
of HDAC3 protein expression has been reported in human 
colon tumours and knocking down of HDAC3 expression 
by RNA interference in colon cancer cell lines resulted in 
growth inhibition, a decrease in cell survival and increased 
apoptosis. Similar effects were observed for HDAC2 and, 
to a lesser extent, for HDAC1 (Wilson et al. 2006). HDAC8 
has been implicated in smooth muscle cell contractility 
(Waltregny et al. 2005) although its knockdown by RNA 
interference inhibits growth of human lung, colon, and cer-
vical cancer cell lines (Vannini et al. 2004). This shows that 
class I HDACs are essential for cell cycle regulation, pro-
liferation and survival with the exception of HDAC2 which 
is involved in the regulation of apoptosis in tumour cells. 
Altered expression of certain HDACs has been reported in 
tumours compared with normal cells. Increased expression 
of HDAC1 has been found in gastric cancers, oesophageal 
squamous cell carcinoma, hormone-refractory prostate can-
cer, and colon cancer (Choi et al. 2001; Wilson et al. 2006). 
HDAC2 expression is increased in human colon cancer 
(Zhu et al. 2004). HDAC3 expression is increased in human 
tumour samples of colon cancer compared with normal tis-
sue (Shebzukhov et al. 2005). HDAC5 is down-regulated 
in colon cancer (Scanlan et al. 2002). Class I HDACs have 
been shown to be expressed at significantly higher levels in 
ovarian cancers in comparison with normal ovarian tissues, 
with no significant difference in Class II HDAC expression 
between the two groups (Khabele et al. 2007). Furthermore, 
the high expression of class 1 HDACs (HDAC1, 2, and 3) 
has been associated with poor prognosis in endometrioid 
subtypes of ovarian and endometrial carcinomas (Weichert 
et al. 2008). In addition, the expression levels were consid-
erably different in specific tumour histological subtypes 
with mucinous carcinomas showing the highest positivity 
rates (71 %); followed by high-grade serous (64 %), clear 
cell (54 %) and endometrioid subtypes (36 %). HDAC class 
I expression was generally higher in strongly proliferat-
ing tumours (Khabele et al. 2007; Weichert et al. 2008). A 
recent study using 115 ovarian tumour tissues confirmed 
that expression of nuclear HDAC1, HDAC2 and HDAC3 
proteins increased stepwise in benign, borderline and 
malignant tumours. Analysis of the effect of specific iso-
forms of HDACs using siRNA against HDAC1, HDAC2 
and HDAC3 on the ovarian carcinoma cell lines, SKOV3, 
OVCAR3, IGROV-1, ES-2, TOV112D, A2780 and A2780/
CDDP showed that knockdown of HDAC1 considerably 
reduced the proliferation of ovarian carcinoma cells, while 
knockdown of HDAC3 reduced cell migration (Hayashi 
et al. 2010). This indicates that HDAC enzymes especially 
class I have important roles in ovarian carcinogenesis 
which provides a rationale for targeted inhibition of HDAC 
enzyme in the treatment of ovarian cancer.
Therapeutic implications of HDAC inhibitors
HDAC inhibitors are amongst the most promising thera-
peutic targets for cancer treatment due to their critical role 
in the regulation of transcription of key genes controlling 
important cellular functions such as cell proliferation, cell 
cycle regulation and apoptosis (Spiegel et al. 2012). The 
balance between histone acetylation and deacetylation is 
required for active gene expression (Secrist et al. 2003). 
The catalytic domain of HDAC is closely conserved from 
bacteria to humans, and the knowledge of its crystal struc-
ture has helped in the development of potent HDAC inhibi-
tors (HDACi) based on the molecular mode of action of 
HDAC. HDAC inhibitor usually consist of a metal-bind-
ing moiety that binds the catalytic metal atom within the 
HDAC active site and a capping group that interacts with 
the residues at the entrance of the active site (Marks et al. 
2001). A linker correctly positions the metal-binding moi-
ety and capping group for interactions in the active site. 
Crystallographic studies have revealed that SAHA (suber-
oylanilide hydroxamic acid or vorinostat) inhibits HDAC 
activity by binding to the active site of the enzyme (Finnin 
et al. 1999; Marks et al. 2001). A number of natural and 
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synthetic compounds have been shown to be able to inhibit 
the activity of class I, II, and IV HDACs. HDACi can be 
divided into several classes: hydroxamic acids, e.g., tri-
chostatin A (TSA) and suberoyl anilide bishydroxamic 
acid (SAHA), short-chain fatty acids, e.g., sodium butyrate 
(NaB), cyclic tetrapeptides (e.g., traposin), and benzamides 
(e.g., MS-275) (Villar-Garea and Esteller 2004). The effi-
cacy of HDAC inhibitors as anticancer agents has been 
demonstrated in a wide range of haematological and solid 
tumour cell lines and in experimental animal models (Saito 
et al. 1999; Drummond et al. 2005).
HDAC inhibitors exhibit the anticancer effects through 
regulation of gene expression by histone acetylation and 
through increasing acetylation of other cellular proteins. 
The molecular pathways that trigger cell death by HDAC 
inhibitor in ovarian cancer are not fully understood. But 
there are a number of genes identified to be either up or 
down-regulated following HDACi treatment. These genes 
involved in a variety of cellular processes and networks 
such as those involving the proapoptotic proteins; Fas, Fas 
ligand, Bak, Bax, Bim, BLxl, Bcl2, Caspase 3, and the cell 
cycle regulation proteins such as p21 and p27 (Drummond 
et al. 2005). HDACi treatment has been reported to activate 
caspase-9, caspase-3, and caspase-8 and inhibit anti-apop-
totic Bcl-2 family members (Bcl-2 and Bcl-XL) in breast, 
colon, hematopoietic, lung, melanoma, ovarian, prostatic, 
renal, and stomach cancer cell lines using a novel hydrox-
amate-based HDACI, CG0006 (Hwang et al. 2009). BcL2 
proteins control the intrinsic pathway of apoptosis at the 
mitochondria by preventing the release of the cytochrome 
c. Therefore, the inhibition of Bcl-2 and Bcl-XL by HDACi 
treatment promotes the release of cytochrome c followed 
by caspase-9 and caspase-3 activation leading to apoptosis. 
As discussed previously, the expression of Bcl2 has been 
shown to protect ovarian cancer cells from the toxic effect 
of cisplatin (Hwang et al. 2009). Thus, HDACi could play 
role in cisplatin resistance in ovarian cancer by modifying 
the expression of the genes could confer resistance to cispl-
atin. It has been shown that HDACi treatment induced the 
accumulation of both proteins p21 and p27, which express 
in low level in untreated ovarian cancer cell lines and have 
important role in cell cycle regulation (Hwang et al. 2009). 
Moreover, specific knockdown by siRNA against HDAC4 
in ovarian carcinoma IGROV-1 induced the expression of 
p21 (Mottet et al. 2009). The up-regulated p21 and p27 bind 
to cyclin-CDK complexes to inhibit their catalytic activ-
ity and induce cell cycle arrest in cancer cells. The study 
showed that over-expression of P21 and p27 correlates with 
increased apoptosis, demonstrating that p21 and p27 levels 
might be essential for HDACi—induced apoptosis (Abukh-
deir and Park 2008). This is just one of the possible path-
ways that HDACi utilise to arrest cancer cell growth. It has 
also been demonstrated that histone deacetylase inhibitors 
exhibit anti-cancer activity and induces apoptosis in ovar-
ian cancer cells via up-regulation of E-cadherin expression 
and accumulation of acetylated histones H3 and H4. The 
study examined the effect of HDACi (SAHA, VPA, TSA, 
and NaB) using human ovarian cancer cell lines (SKOV-
3, OVCAR-3, TOV-21G, OV-90, TOV-112D, OVCA420, 
OVCA429, OVCA432, and OVCA433) (Takai et al. 2004).
Hayashi et al. (2010) has reported that knockdown of 
HDAC3 by siRNA reduced the cell migration with elevated 
E-cadherin expression in ovarian cancer cells. E-cadherin is 
one of the important molecules for adhesion between adja-
cent epithelial cells. When the ovarian epithelial cell under-
goes transformation, the cell can detach from the original 
basement membrane and metastasize throughout the peri-
toneal cavity. E-cadherin is membrane glycoproteins that 
mediate adhesion between cells which is an important 
event in metastasis. Loss of E-cadherin has been associated 
with ovarian cancer metastasis (Sawada et al. 2008). E-cad-
herin might have tumour suppressor function in ovarian 
carcinoma because it has been reported to be silenced by 
DNA hypermethylation in human breast and prostate car-
cinomas (Graff et al. 1995). The up-regulated E-cadherin 
after HDACi treatment in ovarian carcinoma cells indicate 
that this gene also involved in HDACi meditating cell death 
in ovarian cancer (Takai and Narahara 2007).
The generation of reactive oxygen species (ROS) is 
another phenomenon observed in HDAC inhibitor-treated 
cells. It has been reported that HDAC inhibitors; TSA, 
MS-275, FK228 and HC toxin promote the induction of 
DNA damage by a variety of anticancer agents; doxoru-
bicin, paclitaxel, etoposide, cisplatin, bleomycin, mito-
mycin-C and topotecan, which resulted in enhanced gen-
eration of ROS, then cell death in human ovarian cancer 
cell lines; OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, 
SKOV-3, and TYK-nu (Ozaki et al. 2008). This showed that 
increased generation of ROS play a role in HDAC-medi-
ated cell death. It seems that HDACi-induced cell death 
is through extrinsic apoptotic pathway, which involves 
the cross-linking of certain death-inducing receptors like 
Fas by their legends (Drummond et al. 2005) and conse-
quent activation of caspases 3, 8 and 9. In addition to this, 
HDACi utilises the intrinsic apoptotic pathway through the 
disruption of outer mitochondrial membrane integrity and 
later release of cytochrome c and other pro-apoptotic mol-
ecules. The involvement of these factors and pathways in 
the anti-cancer activity of HDACi need to be investigated. 
In addition, the effects of HDACi can be cell-type-depend-
ent, and different HDACi can have different effects in the 
same cell type as shown by (Ozaki et al. 2008). This pos-
sibly relates to the HDAC-specificity profiles of the differ-
ent compounds and HDACs profile in different cell lines 
since different HDAC isoforms contribute selectively to the 
development of ovarian cancer.
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Another type of HDACi is sphingosine-1-phosphate 
(S1P). S1P is a lipid mediator that can act intracellularly 
as an HDAC inhibitor (Hait et al. 2009). S1P regulates his-
tone acetylation by binding to HDAC1 and HDAC2. As 
S1P directly inhibits HDACs, it plays an essential role in 
epigenetic regulation of nuclear expression. S1P is aber-
rantly expressed in ovarian cancer and regulates key pro-
cesses involved in ovarian cancer initiation and progres-
sion. Molecular agents that block S1P mediated signalling 
induce cellular apoptosis or inhibit ovarian cancer cell pro-
liferation. Such evidence highlights a potential role for S1P 
as a drug target in ovarian cancer (Dai et al. 2014).
SAHA has been approved by the US Food and Drug 
Administration for the treatment of cutaneous T-cell lym-
phoma (CTCL), a form of non-Hodgkin’s lymphoma. 
Romidepsin is the second HDAC inhibitor to be approved 
by the FDA for the treatment of CTCL. Romidepsin has a 
very different chemical structure compared to vorinostat 
(Fig. 3). Romidepsin is a selective inhibitor for class I 
HDACs, whereas vorinostat is a pan-HDAC inhibitor 
(Campas-Moya 2009). Most HDACi are not specific to sub-
classes of HDAC enzymes. They inhibit many of the known 
mammalian HDACs. There has been increased attention 
over the past several years to create selective HDAC inhibi-
tor. Given that specific HDAC isoform has specific function 
in cancer, selective HDAC inhibitors will be very useful 
in cancer treatment. This led to several class-selective and 
some isoform-selective inhibitors such as MS-275. MS-275 
is more active against HDAC1 than against HDAC3 (Hu 
et al. 2003). Depsipeptide is more potent against HDAC1 
and HDAC2 than against HDAC4 and HDAC6 (Furumai 
et al. 2002). 2f-MC1568 and 4a-MC1511 HDAC inhibitors 
are derivative of aroyl-pyrrolyl-hydroxyamides (APHAs) 
2f-MC1568 was selective to class II but with poor inhibi-
tory activity; however, 4a-MC1511 showed effective inhib-
itory activity against class II and to less extent to class I 
(Mai et al. 2005). Therefore, further studies are necessary 
in order to create HDAC isoform specific inhibitors.
The effect of HDACi in the treatment of epithelial ovar-
ian cancer has been reported by Takai et al. (2006). The 
study investigated the effect of scriptaid, a member of the 
hydroxamic class of HDAC inhibitors that is selective for 
class I HDACs on Ishikawa endometrial cancer cell line, 
SKOV-3 ovarian cancer cell line, and normal human endo-
metrial epithelial cells. The data showed that Scriptaid 
induced growth inhibition and increased acetylation of H3 
and H4 histone for both endometrial and ovarian cancer 
cell lines. While normal endometrial epithelial cells were 
viable following treatment with similar doses of Scriptaid. 
The study showed the effectiveness of HDACi in mediat-
ing tumour cell selective killing compared with the normal 
cell. This may be because cancer cells have several genetic 
defects and, unlike normal cells, are unable to reverse the 
adverse effects of HDAC inhibitors. Vorinostat has been 
reported to induce cell death and increase caspase-3 activ-
ity in three ovarian cancer cell lines (OVCAR-3, SK-OV-
3, and A2780) and in primary ovarian cancer cells isolated 
from malignant ascites collected from five patients with 
stage III ovarian carcinomas.
Furthermore, 2780AD, a doxorubicin-resistant ovarian 
cancer cell line cells were responsive to vorinostat (Sonne-
mann et al. 2006). Pre-treatment with vorinostat and tri-
chostatin A (TSA) has been shown to enhance the cytotox-
icity of DNA-targeting agents such as VP-16, ellipticine, 
doxorubicin, and cisplatin but not that of drugs which do 
not target the DNA, like the antimetabolite 5-fluorouracil 
(Kim et al. 2003). In addition, valproic acid (2-propylpen-
tanoic acid; VPA), an HDAC inhibitor that inhibits both 
class I and II HDACs, has been reported to have synergis-
tic cytotoxicity with cisplatin in human ovarian carcinoma 
cells (SK-OV-3, OVCAR-3, TOV-21G, A2780 and A2780/
CP70) and can restore platinum sensitivity in the acquired 
cisplatin-resistance cells (Lin et al. 2008). Pre-clinical 
in vitro studies on the effect of PXD101, a class I and II 
HDAC inhibitor showed this HDACi exhibit single-agent 
antitumour activity on human A2780 ovarian cancer xeno-
grafts. This effect improved when combined with carbopl-
atin treatment (Qian et al. 2006).
Clinical trials showed the limited therapeutic of some of 
HDACi such as TSA and trapoxin because they have poor 
Fig. 3  Vorinostat inhibits HDAC activity by binding to the pocket of 
the catalytic site. The hydroxamic acid moiety of vorinostat binds to 
a zinc atom (pink); this allows the rest of the molecule to lie along the 
surface of the HDLP protein. Adapted from Marks et al. (2001)
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bioavailability and toxic side effects at high doses. Other 
HDACi are degraded after i.v. administration like sodium 
butyrate and phenylbutyrate thus requiring high doses to 
achieve maximum tumour killing (Warrell et al. 1998). It 
has been shown that vorinostat-treated ovarian cancer cell 
lines and in primary cancer cells derived from malignant 
ascites obtained from five patients with stage III ovarian 
cancer had cytotoxic effect as a single agent (Sonnemann 
et al. 2006). A phase II trial of vorinostat in platinum-resist-
ant/refractory epithelial ovarian patients showed progres-
sion-free survival over 6 months, with few having a partial 
response. However, vorinostat has toxic effects such as 
thrombocytopenia, neurologic complaints and pain which 
limit its effectiveness (Modesitt et al. 2008). This provides 
an evidence that HDAC inhibitors could have a potential 
role in the treatment of ovarian cancer, but there is need to 
develop HDAC inhibitor that has a tolerable side effect and 
efficient in destroying cancer cells.
Conclusions and future perspectives
Ovarian cancer comprises a heterogenous group of tumours 
that are associated with a specific prognosis and drug 
resistance patterns. At present, there is a growing need for 
novel therapy to improve overall survival and disease-free 
survival hence reducing ovarian cancer related mortality. 
Addressing resistance to chemotherapy should be one of 
the strategies to target resistance to chemotherapy. As most 
drug resistance is at the level of gene expression, HDAC 
inhibitors are amongst the most promising therapeutic tar-
gets for cancer treatment due to their critical role in the 
regulation of transcription of key genes controlling impor-
tant cellular functions such as cell proliferation, cell cycle 
regulation and apoptosis (Spiegel et al. 2012). While the 
preliminary results are promising, robust clinical trials are 
needed to ascertain whether this treatment offers benefi-
cial clinical outcomes with tolerated side-effect profiles. A 
number of other drugs that target unique cancer pathways 
are undergoing trials. Given the complexity of disease man-
agement and the vast armamentarium of available drugs, 
utilising genetic tumour profiles has the potential to stratify 
patients and help select the best drug regimen that provides 
a superior benefit to risk ratio for each individual patient.
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